Blood and urinary cytokine balance and renal outcomes at cardiac surgery.
Acute kidney injury
Biomarkers
Cardiac surgery
Cytokines
H-FABP
IL-12p40
IL-1RA
Midkine
TNFsr2
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
08 12 2021
08 12 2021
Historique:
received:
18
03
2021
accepted:
24
11
2021
entrez:
8
12
2021
pubmed:
9
12
2021
medline:
11
3
2022
Statut:
epublish
Résumé
Increased perioperative pro-inflammatory biomarkers, renal hypoperfusion and ischemia reperfusion injury (IRI) heighten cardiac surgery acute kidney injury (CS-AKI) risk. Increased urinary anti-inflammatory cytokines attenuate risk. We evaluated whether blood and urinary anti-inflammatory biomarkers, when expressed as ratios with biomarkers of inflammation, hypoperfusion and IRI are increased in CS-AKI patients. Preoperative and 24-h postoperative blood and urinary pro-inflammatory and anti-inflammatory cytokines, blood VEGF and H-FABP (hypoperfusion biomarkers), and MK, a biomarker for IRI, were measured in 401 cardiac surgery patients. Pre- and postoperative concentrations of biomarkers and selected ratios thereof, were compared between non-CS-AKI and CS-AKI patients. Compared with non-CS-AKI, blood pro-inflammatory (pre- and post-op TNFα, IP-10, IL-12p40, MIP-1α, NGAL; pre-op IL-6; post-op IL-8, MK) and anti-inflammatory (pre- and post-op sTNFsr1, sTNFsr2, IL-1RA) biomarkers together with urinary pro-inflammatory (pre- and post-op uIL-12p40; post-op uIP-10, uNGAL) and anti-inflammatory (pre- and post-op usTNFsr1, usTNFsr2, uIL-1RA) biomarkers, were significantly higher in CS-AKI patients. Urinary anti-inflammatory biomarkers, when expressed as ratios with biomarkers of inflammation (blood and urine), hypoperfusion (blood H-FABP and VEGF) and IRI (blood MK) were decreased in CS-AKI. In contrast, blood anti-inflammatory biomarkers expressed as similar ratios with blood biomarkers were increased in CS-AKI. The urinary anti-inflammatory response may protect against the injurious effects of perioperative inflammation, hypoperfusion and IRI. These finding may have clinical utility in bioprediction and earlier diagnosis of CS-AKI and informing future therapeutic strategies for CS-AKI patients.
Sections du résumé
BACKGROUND
Increased perioperative pro-inflammatory biomarkers, renal hypoperfusion and ischemia reperfusion injury (IRI) heighten cardiac surgery acute kidney injury (CS-AKI) risk. Increased urinary anti-inflammatory cytokines attenuate risk. We evaluated whether blood and urinary anti-inflammatory biomarkers, when expressed as ratios with biomarkers of inflammation, hypoperfusion and IRI are increased in CS-AKI patients.
METHODS
Preoperative and 24-h postoperative blood and urinary pro-inflammatory and anti-inflammatory cytokines, blood VEGF and H-FABP (hypoperfusion biomarkers), and MK, a biomarker for IRI, were measured in 401 cardiac surgery patients. Pre- and postoperative concentrations of biomarkers and selected ratios thereof, were compared between non-CS-AKI and CS-AKI patients.
RESULTS
Compared with non-CS-AKI, blood pro-inflammatory (pre- and post-op TNFα, IP-10, IL-12p40, MIP-1α, NGAL; pre-op IL-6; post-op IL-8, MK) and anti-inflammatory (pre- and post-op sTNFsr1, sTNFsr2, IL-1RA) biomarkers together with urinary pro-inflammatory (pre- and post-op uIL-12p40; post-op uIP-10, uNGAL) and anti-inflammatory (pre- and post-op usTNFsr1, usTNFsr2, uIL-1RA) biomarkers, were significantly higher in CS-AKI patients. Urinary anti-inflammatory biomarkers, when expressed as ratios with biomarkers of inflammation (blood and urine), hypoperfusion (blood H-FABP and VEGF) and IRI (blood MK) were decreased in CS-AKI. In contrast, blood anti-inflammatory biomarkers expressed as similar ratios with blood biomarkers were increased in CS-AKI.
CONCLUSIONS
The urinary anti-inflammatory response may protect against the injurious effects of perioperative inflammation, hypoperfusion and IRI. These finding may have clinical utility in bioprediction and earlier diagnosis of CS-AKI and informing future therapeutic strategies for CS-AKI patients.
Identifiants
pubmed: 34876054
doi: 10.1186/s12882-021-02621-6
pii: 10.1186/s12882-021-02621-6
pmc: PMC8653550
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
406Informations de copyright
© 2021. The Author(s).
Références
Anesthesiology. 2000 Nov;93(5):1210-6; discussion 5A
pubmed: 11046208
Cytokine. 2013 Jan;61(1):275-84
pubmed: 23137784
J Renal Inj Prev. 2015 Jun 01;4(2):20-7
pubmed: 26060833
Nephron Exp Nephrol. 2008;109(4):e102-7
pubmed: 18802372
Comp Med. 2014 Apr;64(2):99-105
pubmed: 24674583
Gen Pharmacol. 1987;18(4):343-6
pubmed: 3609691
Cardiology. 2008;111(1):23-9
pubmed: 18239388
Pediatrics. 2015 Apr;135(4):e945-56
pubmed: 25755241
Ann Thorac Surg. 2007 Feb;83(2):578-85
pubmed: 17257991
Sci Rep. 2019 Nov 18;9(1):16963
pubmed: 31740699
Cytokine. 2004 Jul 21-Aug 7;27(2-3):81-9
pubmed: 15242697
Am J Kidney Dis. 2015 Dec;66(6):993-1005
pubmed: 26253993
Exp Nephrol. 1999 Sep-Dec;7(5-6):438-48
pubmed: 10559642
Nephrol Dial Transplant. 2009 Sep;24(9):2739-44
pubmed: 19349297
Br J Anaesth. 1995 Dec;75(6):724-33
pubmed: 8672321
Int J Clin Exp Med. 2015 May 15;8(5):7577-84
pubmed: 26221302
Clin Transl Sci. 2008 Dec;1(3):200-8
pubmed: 19212447
Contrib Nephrol. 2010;165:1-8
pubmed: 20427949
Br J Anaesth. 2002 Mar;88(3):330-4
pubmed: 11990261
J Am Soc Nephrol. 2008 Apr;19(4):789-97
pubmed: 18256362
Life Sci. 2003 Dec 19;74(5):543-52
pubmed: 14623025
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
J Diabetes Complications. 2016 Mar;30(2):295-9
pubmed: 26790575
J Immunol. 2001 Sep 15;167(6):3463-9
pubmed: 11544339
Kidney Int. 2014 Feb;85(2):431-8
pubmed: 24005224